Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
101.43
-2.39 (-2.30%)
At close: May 13, 2025, 4:00 PM
101.01
-0.42 (-0.41%)
Pre-market: May 14, 2025, 8:59 AM EDT
Gilead Sciences Revenue
Gilead Sciences had revenue of $6.67B in the quarter ending March 31, 2025, a decrease of -0.28%. This brings the company's revenue in the last twelve months to $28.74B, up 4.68% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.74B
Revenue Growth
+4.68%
P/S Ratio
4.40
Revenue / Employee
$1,632,670
Employees
17,600
Market Cap
126.17B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GILD News
- 13 hours ago - Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript - Seeking Alpha
- 1 day ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 6 days ago - Gilead announces $11 billion in new investments in US - Reuters
- 7 days ago - Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment - Business Wire
- 7 days ago - Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 - Business Wire
- 14 days ago - Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
- 14 days ago - Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors - Reuters
- 14 days ago - Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions - CNBC